Bianca Lemos, MD, joins the lab after completing her Medicine internship at the University of Washington. She will be focusing on the effect of inhibiting the replication checkpoint on UV-induced carcinogenesis and will participate in maintaining the Merkel cell carcinoma…
Protein Kinases and Cancer Therapy featured in Oncogenomics textbook. This chapter provides an overview of new and emerging approaches to target protein kinases in cancer therapy. [pdf]
Paul Nghiem, MD, PhD, is featured in an article in the March 1, 2006, issue of Dermatology Times
Dr. Nghiem moves his lab to the University of Washington in Seattle, Washington. Dr. Kawasumi will join him in Seattle in the Fall, and Dr. Heffernan will remain a part of the lab but will physically remain in Boston. New…
Dr. Heffernan did his PhD with William Kaufmann in North Carolina on the replication checkpoint and ultraviolet-induced DNA damage. He brings extraordinary expertise in this field to our lab. He is working on the roles of ATR and Chk1 in…
This website will serve as a unique resource for Merkell cell carcinoma patients and their physicians. Written and conceived together with Sheela Gupta and Linda Wang and implemented by Digizyme, Inc. Click here to view website.
Douglas is a senior at MIT majoring in Biology. He will be working on the transgenic mouse project with a focus on primary keratinocytes.
Adam is a junior at Tufts University majoring in Biology. He will be responsible for maintaining our transgenic mice and focusing on carcinogenesis.
Dr. Kawasumi is working on the development small molecule inhibitors of ATR.
In an ongoing collaboration with Dr. Vicente Planelle's laboratory, ATR has been shown to play a key role in the cellular response to HIV-1 infection in two papers. [MCB 200] & [JBL 203]
Rapamycin and nutrient signaling are profiled in a review with Aly Shamji and Stuart Schreiber. [pdf]
This proposal to study the replication checkpoint and small molecules to regulate it, was rated in the top 4.8% of grants submitted to the Chemical Pathology Study Section of the NIH. It will provide critical funding for our studies through 2008.